Predictive Oncology Files 8-K on Shareholder Nominations
Ticker: AGPU · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1446159
Sentiment: neutral
Topics: shareholder-nomination, corporate-governance, 8-k
TL;DR
Predictive Oncology filed an 8-K for shareholder nominations - board shakeup incoming?
AI Summary
Predictive Oncology Inc. filed an 8-K on October 16, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the company, formerly known as Skyline Medical Inc., is incorporated in Delaware and has its principal business address in Pittsburgh, PA.
Why It Matters
This filing signals potential changes in the company's board composition or strategic direction due to shareholder nominations, which could impact future operations and stock performance.
Risk Assessment
Risk Level: medium — Shareholder nominations can indicate activism or dissatisfaction, potentially leading to significant changes in company leadership or strategy.
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- Exchange Act Rule 14a-11 (legal_document) — Subject of filing
- Skyline Medical Inc. (company) — Former company name
- Delaware (location) — State of incorporation
- Pittsburgh, PA (location) — Business address
FAQ
What is the specific purpose of the shareholder nominations mentioned in the filing?
The filing states the nominations are pursuant to Exchange Act Rule 14a-11, which pertains to shareholder nominations of directors.
When was this 8-K report filed?
The report was filed on October 16, 2025.
What was Predictive Oncology Inc. previously known as?
Predictive Oncology Inc. was formerly known as Skyline Medical Inc.
In which state is Predictive Oncology Inc. incorporated?
The company is incorporated in Delaware.
What is the business address of Predictive Oncology Inc.?
The business address is 91 43rd Street, Suite 110, Pittsburgh, PA 15201.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2025-10-16 17:15:29
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market
Filing Documents
- f8k_101525.htm (8-K) — 20KB
- 0001171843-25-006489.txt ( ) — 181KB
- poai-20251016_lab.xml (EX-101.LAB) — 33KB
- poai-20251016_pre.xml (EX-101.PRE) — 22KB
- poai-20251016.xsd (EX-101.SCH) — 3KB
- f8k_101525_htm.xml (XML) — 4KB
08
Item 5.08 Shareholder Director Nominations. The board of directors (the "Board") of Predictive Oncology, a Delaware corporation (the "Company"), has determined that the Company's 2025 annual meeting of stockholders (the "Annual Meeting") will be held on November 25, 2025, at the offices of DLA Piper LLP (US) at 1001 Liberty Avenue, Suite 500, Pittsburgh, Pennsylvania 15222. The record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting will be October 24, 2025. The Annual Meeting is more than 30 days from the date of the Company's 2024 annual meeting of stockholders. In accordance with the Company's bylaws and the rules and regulations of the Securities and Exchange Commission, stockholders will have until October 26, 2025 (the "Proposal Deadline") to submit stockholder proposals and request proxy access with respect to any business to be considered at the Annual Meeting. To be eligible for inclusion, any such proposal should be directed to the following address: Predictive Oncology Inc. Attention: Secretary 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 The Company anticipates mailing definitive proxy materials for the Annual Meeting on or about November 3, 2025. Under the rules and regulations of the Securities and Exchange Commission, the Company undertakes to supplement such materials (and, if necessary, postpone the Annual Meeting) to address any stockholder proposals timely received before the Proposal Deadline. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: October 16, 2025 By: /s/ Josh Blacher Josh Blacher Chief Financial Officer